The US decision to impose a 100 per cent tariff on branded and patented pharmaceutical imports from October 2025 is unlikely to affect Indian exports in the near term, according to industry experts. The announcement by President Donald Trump, made via a post on Truth Social, has triggered debate over the impact on global healthcare supply chains. But experts reportedly point out that the measure excludes generic medicines, which form the bulk of India's pharmaceutical exports to the US.

Tariffs aimed at branded drugs, not generics

"The proposed 100 per cent tariff on branded and patented pharmaceutical imports is unlikely to have an immediate impact on Indian exports, as the bulk of our contribution lies in simple generics," said Namit Joshi, Chairman of the Pharmaceuticals Export Promot

See Full Page